Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility

Seamless phase II/III clinical trials combine traditional phases II and III into a single trial that is conducted in two stages, with stage 1 used to answer phase II objectives such as treatment selection and stage 2 used for the confirmatory analysis, which is a phase III objective. Although seamless phase II/III clinical trials are efficient because the confirmatory analysis includes phase II data from stage 1, inference can pose statistical challenges. In this paper, we consider point estimation following seamless phase II/III clinical trials in which stage 1 is used to select the most effective experimental treatment and to decide if, compared with a control, the trial should stop at stage 1 for futility. If the trial is not stopped, then the phase III confirmatory part of the trial involves evaluation of the selected most effective experimental treatment and the control. We have developed two new estimators for the treatment difference between these two treatments with the aim of reducing bias conditional on the treatment selection made and on the fact that the trial continues to stage 2. We have demonstrated the properties of these estimators using simulations. Copyright © 2013 John Wiley & Sons, Ltd.

[1]  Frank Bretz,et al.  Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint , 2007, Statistics in medicine.

[2]  G. Hommel.  Adaptive Modifications of Hypotheses After an Interim Analysis , 2001 .

[3]  Martin Posch,et al.  Testing and estimation in flexible group sequential designs with adaptive treatment selection , 2005, Statistics in medicine.

[4]  Terry M. Therneau,et al.  Optimal two-stage screening designs for survival comparisons , 1990 .

[5]  Christopher Jennison,et al.  Adaptive Seamless Designs: Selection and Prospective Testing of Hypotheses , 2007, Journal of biopharmaceutical statistics.

[6]  John Whitehead,et al.  Estimation following selection of the largest of two normal means. Journal of Statistical Planning and Inference 138, 1629-1638. , 2008 .

[7]  Frank Bretz,et al.  Adaptive designs for confirmatory clinical trials , 2009, Statistics in medicine.

[8]  Richard Simon,et al.  Two-stage selection and testing designs for comparative clinical trials , 1988 .

[9]  Jack Bowden,et al.  Unbiased Estimation of Selected Treatment Means in Two‐Stage Trials , 2008, Biometrical journal. Biometrische Zeitschrift.

[10]  Nigel Stallard,et al.  Point estimates and confidence regions for sequential trials involving selection , 2005 .

[11]  Nigel Stallard,et al.  Dose selection in seamless phase II/III clinical trials based on efficacy and safety , 2009, Statistics in medicine.

[12]  John Whitehead,et al.  On the bias of maximum likelihood estimation following a sequential test , 1986 .

[13]  G. Wassmer,et al.  Comments on the Draft Guidance on “Adaptive Design Clinical Trials for Drugs and Biologics” of the U.S. Food and Drug Administration , 2010, Journal of biopharmaceutical statistics.

[14]  James F. Troendle,et al.  Conditional estimation following a group sequential clinical trial , 1999 .

[15]  Frank Bretz,et al.  Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology , 2009, Statistics in medicine.

[16]  Harold B. Sackrowitz,et al.  Two stage conditionally unbiased estimators of the selected mean , 1989 .

[17]  Frank Bretz,et al.  Adaptive Dunnett tests for treatment selection , 2008, Statistics in medicine.

[18]  Margaret Sullivan Pepe,et al.  Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futility. , 2012, Statistics in medicine.

[19]  L Shen,et al.  An improved method of evaluating drug effect in a multiple dose clinical trial , 2001, Statistics in medicine.

[20]  Werner Brannath,et al.  Shrinkage estimation in two‐stage adaptive designs with midtrial treatment selection , 2013, Statistics in medicine.

[21]  H. Schäfer,et al.  Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches , 2001, Biometrics.

[22]  Nigel Stallard,et al.  Sequential designs for phase III clinical trials incorporating treatment selection , 2003, Statistics in medicine.

[23]  Frank Bretz,et al.  Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts , 2006, Biometrical journal. Biometrische Zeitschrift.

[24]  Mark C. K. Yang,et al.  Interval estimation for drop-the-losers designs , 2010 .

[25]  W. Brannath,et al.  Selection and bias—Two hostile brothers , 2009, Statistics in medicine.